Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients...